These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1649751)

  • 1. Ontogeny of mu- and kappa-opiate receptor control of the hypothalamo-pituitary-adrenal axis in rats.
    Adamson WT; Windh RT; Blackford S; Kuhn CM
    Endocrinology; 1991 Aug; 129(2):959-64. PubMed ID: 1649751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat.
    Ignar DM; Kuhn CM
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1287-95. PubMed ID: 2175800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
    Milanés MV; Vargas ML; Martín MI
    Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of U50,488H fails to produce hypothalamo-pituitary-adrenal axis tolerance in neonatal rats.
    Ignar DM; Windh RT; Kuhn CM
    Neuropharmacology; 1992 Feb; 31(2):143-8. PubMed ID: 1553027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat.
    Fox DA; Burks TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):456-62. PubMed ID: 2831341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level.
    Alcaraz C; Milanés MV; Vargas ML
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1385-9. PubMed ID: 8396634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical axis level.
    Alcaraz C; Vargas ML; Fuente T; Milanés MV
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1602-6. PubMed ID: 8396640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ; Morris BJ; Herz A
    J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mu- and kappa-opiate receptor control of prolactin secretion in rats: ontogeny and interaction with serotonin.
    Blackford SP; Little PJ; Kuhn CM
    Endocrinology; 1992 Dec; 131(6):2891-7. PubMed ID: 1332851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mu-Opioid agonists stimulate growth hormone secretion in immature rats.
    Eason MG; Francis RS; Kuhn CM
    Neuroendocrinology; 1996 Jun; 63(6):489-97. PubMed ID: 8793890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
    Iyengar S; Kim HS; Wood PL
    J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
    Iyengar S; Kim HS; Wood PL
    Brain Res; 1987 Dec; 435(1-2):220-6. PubMed ID: 2892574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
    Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
    J Pharmacol Exp Ther; 1996 May; 277(2):877-84. PubMed ID: 8627570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
    Eisenberg RM
    J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid modulation of the fetal hypothalamic-pituitary-adrenal axis: the role of receptor subtypes and route of administration.
    Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):129-35. PubMed ID: 9103489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.